Compassionate use of bedaquiline in the treatment of pulmonary XDR-TB

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 12, 2014, Pages 1522-1523

  Danckers, Mauricio ^a   Lesko, Melissa B ^a   Adamson, Rosemary ^b   Leibert, Eric ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CYCLOSERINE; ETHIONAMIDE; ISONIAZID; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; BACTERIUM CULTURE; CASE REPORT; COMPASSIONATE USE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIRECTLY OBSERVED THERAPY; DISEASE SEVERITY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEVER; HEMOPTYSIS; HUMAN; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; IMMIGRATION; LETTER; LOBECTOMY; LUNG INFILTRATE; MALE; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; SPUTUM SMEAR; THORAX RADIOGRAPHY; UNITED STATES; COMPUTER ASSISTED TOMOGRAPHY; DRUG COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADULT; ANTITUBERCULAR AGENTS; COMPASSIONATE USE TRIALS; DIARYLQUINOLINES; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MALE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84911386960     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0338     Document Type: Letter

References (5)

1. Andries K, Verhasselt P, Guillemont J, et al., A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-227.
2. Tiberi S, De Lorenzo S, Centis R, Viggiani P, D'Ambrosio L, Migliori G B. Bedaquiline in MDR/XDR-TB cases: First experience on compassionate use. Eur Respir J 2014; 43: 289-292.
3. van Halsema C, Humphreys S, Bonington A. Extensively drugresistant tuberculosis: Early access to bedaquiline for a UK patient. Eur Respir J 2014; 43: 292-294.
4. Huitric E, Verhasselt P, Andries K, Hoffner S E. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007; 51: 4202-4204.
5. US Food and Drug Administration. Anti-Infective Drugs Advisory Committee Meeting Briefing Document. TMC207 (bedaquiline) treatment of patients with MDR-TB. NDA 204-384 28. Washington, DC, USA: FDA: November 2012. http: //www.fda. gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm329260.pdf. Accessed September 2014